Publications 2026

Nagel R, Kochavi A, Flem-Karlsen K, Adhikary M, Gal-On Y, Klaoudatou MG, Champagne J, Valcanover L, Palashati H, Nielsen MM, Feng X, Körner PR, Giebel L, Yang W, Velds A, Hoekman L, Bleijerveld OB, van Tellingen O, Olweus J, Agami R (2026)
Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production
Cancer Res, 86 (14), 3480-3501
DOI 10.1158/0008-5472.CAN-25-4773, PubMed 42095547

Talty R, Brooks VT, McGeary MK, Milette S, Zheng S, Flem-Karlsen K, Daniels A, Deshmukh M, Park K, Caraccio W, Yan H, Echeandia-Francis C, McNamara M, Hong S, Kirwin DS, Olino K, Johnson CH, Bosenberg M, Micevic G, Roy SF (2026)
Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade
Mol Cancer Ther, 25 (5), 759-770
DOI 10.1158/1535-7163.MCT-25-0667, PubMed 41423587

Publications 2025

Flem-Karlsen K, Talty R, McGeary MK, Park K, Thakral D, Brooks VT, Daniels AJ, Damsky W, Roy SF, Micevic G, Bosenberg M (2025)
Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
Cancer Res, 85 (21), 4139-4150
DOI 10.1158/0008-5472.CAN-24-1952, PubMed 40828991

Publications 2024

Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, Nowosad A, Roda N, Makhzami S, Bervoets G, Maciel LF, Pulido-Vicuña CA, Pollaris L, Seurinck R, Zhao F, Flem-Karlsen K, Damsky W, Chen L, Karagianni D, Cinque S, Kint S, Vandereyken K, Rombaut B, Voet T, Vernaillen F, Annaert W, Lambrechts D, Boecxstaens V, Saeys Y, van den Oord J et al. (2024)
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Cell, 187 (1), 166-183.e25
DOI 10.1016/j.cell.2023.11.037, PubMed 38181739

Publications 2023

Benjakul S, Anthi AK, Kolderup A, Vaysburd M, Lode HE, Mallery D, Fossum E, Vikse EL, Albecka A, Ianevski A, Kainov D, Karlsen KF, Sakya SA, Nyquist-Andersen M, Gjølberg TT, Moe MC, Bjørås M, Sandlie I, James LC, Andersen JT (2023)
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery
PNAS Nexus, 2 (12), pgad403
DOI 10.1093/pnasnexus/pgad403, PubMed 38077689

Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn HN, Sefik E, Cheung JF, Hornick NI, Aizenbud L, Joshi NS, Kluger H, Iwasaki A, Bosenberg MW, Flavell RA (2023)
IL-7R licenses a population of epigenetically poised memory CD8⁺ T cells with superior antitumor efficacy that are critical for melanoma memory
Proc Natl Acad Sci U S A, 120 (30), e2304319120
DOI 10.1073/pnas.2304319120, PubMed 37459511

Publications 2022

Akbar R, Bashour H, Rawat P, Robert PA, Smorodina E, Cotet TS, Flem-Karlsen K, Frank R, Mehta BB, Vu MH, Zengin T, Gutierrez-Marcos J, Lund-Johansen F, Andersen JT, Greiff V (2022)
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies
MAbs, 14 (1), 2008790
DOI 10.1080/19420862.2021.2008790, PubMed 35293269

Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, Sand KMK, Emrich T, Fischer JAA, Greiff V, Sandlie I, Schlothauer T, Andersen JT (2022)
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
iScience, 25 (2), 103746
DOI 10.1016/j.isci.2022.103746, PubMed 35118359

Nunes-Xavier CE, Mingo J, Emaldi M, Flem-Karlsen K, Mælandsmo GM, Fodstad Ø, Llarena R, López JI, Pulido R (2022)
Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
Front Oncol, 12, 873516
DOI 10.3389/fonc.2022.873516, PubMed 35692804

Publications 2020

Flem-Karlsen K, Fodstad Ø, Nunes-Xavier CE (2020)
B7-H3 Immune Checkpoint Protein in Human Cancer
Curr Med Chem, 27 (24), 4062-4086
DOI 10.2174/0929867326666190517115515, PubMed 31099317

Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM (2020)
Soluble AXL as a marker of disease progression and survival in melanoma
PLoS One, 15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795

Publications 2019

Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Mol Cancer Ther, 19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265

Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Publications 2018

Flem Karlsen K, McFadden E, Flørenes VA, Davidson B (2018)
Soluble AXL is ubiquitously present in malignant serous effusions
Gynecol Oncol, 152 (2), 408-415
DOI 10.1016/j.ygyno.2018.11.012, PubMed 30448261

Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE (2018)
B7-H3 in Cancer - Beyond Immune Regulation
Trends Cancer, 4 (6), 401-404
DOI 10.1016/j.trecan.2018.03.010, PubMed 29860983

Publications 2017

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
Pigment Cell Melanoma Res, 30 (5), 467-476
DOI 10.1111/pcmr.12599, PubMed 28513992

Publications 2016

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-901
DOI 10.18632/oncotarget.6902, PubMed 26771843